Swipe om te navigeren naar een ander artikel
Understand the choice of recall period for PRO measures based on intended use, characteristics of the disease, treatment, and attributes of studies.
Current practice and considerations were reviewed within several disease areas (overactive bladder, menopausal hot flashes, niacin-induced flushing, osteoarthritis pain, irritable bowel symptoms, benign prostatic hyperplasia, and alopecia).
Rationales were identified for using different recall periods, including event-driven (immediate), daily, up to weekly, and longer than weekly. This work demonstrates that (1) recall depends on what the PRO measure captures, its intended use, and attributes of the disease and study; (2) within the same disease area, recall can vary depending on the concept or phenomenon of interest; (3) recall must consider patient burden and their ability to easily and accurately recall the information requested; and (4) recall must be consistent with the duration of the trial and the scheduled clinic visits.
Shorter recall periods may underestimate symptom burden when symptoms have diurnal or day-to-day fluctuation and may place undue burden on patients. On the other hand, recall intervals that are too long may either over- or underestimate the health state. Therefore, appropriate criteria should be considered given attributes of the disease when selecting an adequate recall period.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development of support labeling claims. Federal Register. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf.
Stull, D. E., Leidy, N. K., Parasuraman, B., & Chassany, O. (2009). Optimal recall periods for patient-reported outcomes: Challenges and potential solutions. CMRO,24(4), 929–942.
Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., et al. (1992). The American-Urological-Association symptom index for benign prostatic hyperplasia. Journal of Urology,148(5), 1549–1557. PubMed
Mularski, R. A., Rosenfeld, K., Coons, S. J., Dueck, A., Cella, D., Feuer, D., et al. (2007). Measuring outcomes in randomized prospective trials in palliative care. Journal of Pain and Symptom Management Volume,34(1), S7–S19. CrossRef
Lipscomb, J., Gotay, C., & Snyder, C. (2007). Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA: A Cancer Journal for Clinicians,57, 278–300. CrossRef
National Cancer Institute. (2008). The nation’s investment in cancer research: A plan and budget proposal for fiscal year 2008. NIH Publication No. 06–6090. Available at: http://plan.cancer.gov. Accessed 22 Aug 2008.
Coronary Drug Project Group. (1975). Clofibrate and niacin in coronary heart disease. Jama,231(4), 360–381. CrossRef
Furlong, W. B., Feeny, D., & Yandow, S. (2005). Patient-focused measures of functional health status and health-related quality of life in pediatric orthopedics: A case study in measurement selection. Health and Quality of Life Outcomes, (3), 1477–7525.
Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J., & Stitt, L. W. (1988). Validation-study of WOMAC: A health-status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug-therapy in patients with osteo-arthritis of the hip or knee. Journal of Rheumatology,15(12), 1833–1840. PubMed
Camilleri, M., Chey, W. Y., Mayer, E. A., Northcutt, A. R., Heath, A., Dukes, G. E., et al. (2001). A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Archives of Internal Medicine,161(14), 1733–1740. PubMedCrossRef
Leventer, S., Raudibaugh, K., Frissora, C., Mangel, A., Galbraith, K. B., Kucharik, R., et al. (2005). The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology,128(4), A94.
Nyhlin, H., Bang, C., Elsborg, L., Silvennoinen, J., Holme, I., Ruegg, P., et al. (2004). A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scandinavian Journal of Gastroenterology,39(2), 119–126. PubMedCrossRef
Miner, P., Stanton, D. B., Carter, F., Caras, S., Krause, G., & Steinborn, C. (2004). Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): Efficacy and safety in a 3 months US study. American Journal of Gastroenterology,99(10), S277.
Fehnel, S., Johnston, J., Kurtz, C., & Mangel, A. (2006). Assessing global change and symptom severity in subjects with IBS: Qualitative item testing. American Journal of Gastroenterology, 101, S483.
Feinstein, R. P. (2007). Androgenetic Alopecia. EMedicine (from WebMD).
Olsen, E. A. (2001). Female pattern hair loss: Clinical features and potential hormonal factors. Journal of the American Academy of Dermatology,45(3), S69. CrossRef
Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., et al. (2004). A randomized, placebo-controlled trial of 5 and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology,50(4), 541–553. PubMedCrossRef
Revicki, D. A., Camilleri, M., Kuo, B., Norton, J. N., Murray, L., Palsgrove, A., & Parkman, H. P. (2009). Development and content validity of a gastroparesis cardinal symptom index daily diary. Alimentary Pharmacology & Therapeutics, 30(6), 670–680.
Revicki, D. A., Margolis, M. K., Bush, E. N., DeRogatis, L. R., & Hanes, V. (2011). Content validity of the female sexual function index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. Journal of Sexual Medicine (Epub ahead of print).
- Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration
Josephine M. Norquist
- Springer Netherlands